MRG003 With Gemcitabine for Second-line Advanced PDAC

Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention

This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c

New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients

A new daily pill called daraxonrasib, which targets a gene behind pancreatic cancer, nearly doubled overall survival time for patients with

New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'

Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine for metastatic pancreatic cancer. This acceler

Promising pancreatic cancer drug may unlock new class of treatments targeting cancer's master switch

The article discusses a promising new drug that targets pancreatic tumors and may have revealed a "master switch" for cancer. The treatment